Bajaj Healthcare Ltd. has reappointed Sajankumar Bajaj as Chairman & Managing Director, reinforcing leadership continuity. For the December 2025 quarter, the company reported consolidated revenue from operations of ₹1.61 billion and net profit of ₹156.7 million. Strong demand in pharmaceuticals and APIs supported growth, despite industry-wide margin pressures.
Bajaj Healthcare Ltd., a leading pharmaceutical and API manufacturer, announced its December 2025 quarter results alongside a key leadership update. Sajankumar Bajaj has been reappointed as Chairman & Managing Director, ensuring strategic stability as the company continues to expand its footprint in the healthcare sector.
Financially, Bajaj Healthcare posted ₹1.61 billion in consolidated revenue from operations and a net profit of ₹156.7 million for Q3 FY26. The results reflect steady demand for active pharmaceutical ingredients (APIs), formulations, and nutraceutical products, though rising input costs and competitive pressures impacted margins.
Key Highlights
-
Leadership Update: Sajankumar Bajaj reappointed as CMD.
-
Revenue from Operations: ₹1.61 billion in Q3 FY26.
-
Net Profit: ₹156.7 million.
-
Growth Drivers: Demand for APIs, formulations, and nutraceuticals.
-
Challenges: Margin pressures due to higher input costs.
-
Outlook: Continued focus on innovation, cost efficiency, and global expansion.
This combination of leadership continuity and resilient financial performance positions Bajaj Healthcare to strengthen its role in India’s pharmaceutical industry.
Sources: Bajaj Healthcare Ltd. – Exchange Filing (Jan 2026), Business Standard, Moneycontrol.